Welcome to our dedicated page for PUMA BIOTECHNOLOGY SEC filings (Ticker: PBYI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Puma Biotechnology SEC filings document an oncology biopharmaceutical business whose reported net product revenue comes from sales of NERLYNX®, its commercial oral neratinib product for HER2-positive breast cancer. Form 8-K reports furnish quarterly and annual operating results, financial-condition updates and exhibit press releases, including disclosures on revenue categories, cost of sales and guidance.
Proxy materials cover board matters, executive compensation and equity-award information, while material-event filings record governance actions such as amendments to the company’s bylaws. The filing record also provides formal context for common stock listed on the Nasdaq Global Select Market and development disclosures related to alisertib and Puma’s oncology programs.
Puma Biotechnology (PBYI) reported Q3 2025 results. Total revenue was $54.5 million, with product revenue of $51.9 million and royalty revenue of $2.6 million. Net income was $8.8 million, or $0.17 per diluted share. Operating costs and expenses were $44.9 million, yielding income from operations of $9.6 million.
For the nine months ended September 30, 2025, revenue was $152.9 million and net income was $17.7 million. Operating cash flow totaled $27.4 million. Cash, cash equivalents and marketable securities were $94.4 million as of September 30, 2025. Long-term debt, net, was $0 at quarter-end, and the current portion of long-term debt was $33.7 million.
Stockholders’ equity rose to $115.3 million from $92.1 million at year-end. Shares outstanding were 50,391,107 as of November 3, 2025. The company continues to commercialize NERLYNX and to develop alisertib under its license from Takeda.
Puma Biotechnology (PBYI) reported that it issued a press release announcing financial results for the third quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1 to this report.
The company states the information under Item 2.02 is being furnished, not filed under the Exchange Act and will not be incorporated by reference into other filings. Additional exhibits include Exhibit 104 (Cover Page Interactive Data File in inline XBRL).
Form 4 filing overview: Puma Biotechnology (PBYI) Chief Financial Officer Maximo F. Nougues reported two open-market sales of company common stock executed on 07/08/2025 and 07/09/2025.
- Shares sold: 5,587 shares at $3.533 on 07/08/2025 and 3,935 shares at $3.535 on 07/09/2025, totalling 9,522 shares.
- Proceeds: Approximately $33,600 based on the disclosed sale prices.
- Post-sale ownership: 204,229 shares held directly after the second transaction, down from an estimated 213,751 shares before the first sale—an ownership reduction of roughly 4.5%.
- Rule 10b5-1 plan: The filing states the transactions were effected under a pre-established Rule 10b5-1(c) trading plan adopted on 12-14-2020.
The reported activity is routine insider selling rather than a grant or option exercise. Because the sales were pre-planned and represent a modest fraction of the CFO’s remaining stake, the market impact is typically viewed as neutral to slightly negative; insider sales can raise questions about confidence, but the use of a long-standing 10b5-1 plan mitigates concerns of opportunistic timing.
Puma Biotechnology, Inc. (PBYI) Form 4 filing: Senior Vice President of Regulatory Affairs Douglas M. Hunt disclosed two open-market sales executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on 12-14-2020.
- 07/08/2025: Sold 4,374 common shares at $3.533; post-sale holding 168,337 shares.
- 07/09/2025: Sold 3,443 common shares at $3.535; post-sale holding 164,894 shares.
The transactions total 7,817 shares (~4.6% of his reported direct ownership) and were filed by one reporting person. No derivative transactions were reported. Hunt remains an officer of the company.